We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Catalyst Pharmaceutical (CPRX - Free Report) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?
Catalyst Pharmaceutical's Business In-Depth
With that in mind, let's take a look at Catalyst Pharmaceutical's main business drivers. Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, such as Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy (initially infantile spasms) and Tourette syndrome.
In October 2012, Catalyst in-licensed rights to Firdapse (amifampridine phosphate) from BioMarin Pharmaceutical Inc. to develop and commercialize the product in the United States. Firdapse is currently approved in the European Union as well as in the United States for the symptomatic treatment of LEMS in adults. LEMS is an ultra-rare disease and the company estimates approximately 3,000 LEMS patients in the United States.
The company is also strengthening the commercial portfolio of Firdapse. It already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population. As a result, these patents will now provide intellectual property protection to Firdapse through 2034.
Catalyst also recently received an FDA approval for its supplemental new drug application (sNDA) for Firdapse (amifampridine) tablets in 10 mg dosage to include pediatric patients (six years and older) for treating LEMS.
Apart from Firdapse, Catalyst Pharmaceuticals is working on a generic version of Lundbeck’s Sabril (vigabatrin), CPP-109, for the treatment of infantile spasms and complex partial seizures. The company is also looking towards opportunities to diversify its business as well as invest in innovative opportunities for rare diseases.
Catalyst recorded revenues worth $141 million for 2021, reflecting an increase of 18% on a year-over-year basis
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Catalyst Pharmaceutical, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in November 2012 would be worth $33,678.16, or a gain of 3,267.82%, as of November 14, 2022, according to our calculations. This return excludes dividends but includes price appreciation.
The S&P 500 rose 189.37% and the price of gold increased -1.54% over the same time frame in comparison.
Looking ahead, analysts are expecting more upside for CPRX.
Catalyst’s earnings and revenues beat estimates for third-quarter 2022. The company’s lead drug Firdapse, approved for treating Lambert-Eaton Myasthenic Syndrome — an ultra-rare disease — witnessed an encouraging uptake since its launch in 2019. Zacks analysts are optimistic about this trend and expect the same to continue in 2022. The company’s efforts to develop Firdapse for other rare neuromuscular indications are also impressive. The FDA recently approved the label expansion of Firdapse for treating LEMS in pediatric patients, which is likely to boost Catalyst’s top line. The stock has outperformed the industry year to date. However, overdependence on Firdapse for growth and the lack of any other promising candidates in its pipeline are major concerns. The stiff competition also remains a woe.
Over the past four weeks, shares have rallied 16.73%, and there have been 3 higher earnings estimate revisions in the past two months for fiscal 2022 compared to none lower. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Catalyst Pharmaceutical (CPRX - Free Report) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?
Catalyst Pharmaceutical's Business In-Depth
With that in mind, let's take a look at Catalyst Pharmaceutical's main business drivers. Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, such as Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy (initially infantile spasms) and Tourette syndrome.
In October 2012, Catalyst in-licensed rights to Firdapse (amifampridine phosphate) from BioMarin Pharmaceutical Inc. to develop and commercialize the product in the United States. Firdapse is currently approved in the European Union as well as in the United States for the symptomatic treatment of LEMS in adults. LEMS is an ultra-rare disease and the company estimates approximately 3,000 LEMS patients in the United States.
The company is also strengthening the commercial portfolio of Firdapse. It already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population. As a result, these patents will now provide intellectual property protection to Firdapse through 2034.
Catalyst also recently received an FDA approval for its supplemental new drug application (sNDA) for Firdapse (amifampridine) tablets in 10 mg dosage to include pediatric patients (six years and older) for treating LEMS.
Apart from Firdapse, Catalyst Pharmaceuticals is working on a generic version of Lundbeck’s Sabril (vigabatrin), CPP-109, for the treatment of infantile spasms and complex partial seizures. The company is also looking towards opportunities to diversify its business as well as invest in innovative opportunities for rare diseases.
Catalyst recorded revenues worth $141 million for 2021, reflecting an increase of 18% on a year-over-year basis
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Catalyst Pharmaceutical, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in November 2012 would be worth $33,678.16, or a gain of 3,267.82%, as of November 14, 2022, according to our calculations. This return excludes dividends but includes price appreciation.
The S&P 500 rose 189.37% and the price of gold increased -1.54% over the same time frame in comparison.
Looking ahead, analysts are expecting more upside for CPRX.
Catalyst’s earnings and revenues beat estimates for third-quarter 2022. The company’s lead drug Firdapse, approved for treating Lambert-Eaton Myasthenic Syndrome — an ultra-rare disease — witnessed an encouraging uptake since its launch in 2019. Zacks analysts are optimistic about this trend and expect the same to continue in 2022. The company’s efforts to develop Firdapse for other rare neuromuscular indications are also impressive. The FDA recently approved the label expansion of Firdapse for treating LEMS in pediatric patients, which is likely to boost Catalyst’s top line. The stock has outperformed the industry year to date. However, overdependence on Firdapse for growth and the lack of any other promising candidates in its pipeline are major concerns. The stiff competition also remains a woe.
Over the past four weeks, shares have rallied 16.73%, and there have been 3 higher earnings estimate revisions in the past two months for fiscal 2022 compared to none lower. The consensus estimate has moved up as well.